The CNS Control of Glucose Metabolism (Acta Neurochirurgica Supplement, nr. 31)
De (autor) E.H. Groteen Limba Engleză Paperback – 17 Jun 1981
Din seria Acta Neurochirurgica Supplement
-
40%
Preț: 434.74 lei
-
5%
Preț: 1231.93 lei
-
9%
Preț: 1585.33 lei
-
5%
Preț: 1681.25 lei
-
5%
Preț: 1126.61 lei
-
5%
Preț: 1489.58 lei
-
nou
Preț: 922.60 lei
-
5%
Preț: 781.26 lei
-
5%
Preț: 647.41 lei
-
5%
Preț: 437.47 lei
-
5%
Preț: 452.97 lei
-
5%
Preț: 475.45 lei
-
5%
Preț: 470.34 lei
-
5%
Preț: 450.28 lei
-
5%
Preț: 442.14 lei
-
5%
Preț: 272.55 lei
-
5%
Preț: 438.32 lei
-
5%
Preț: 449.98 lei
-
5%
Preț: 270.22 lei
-
5%
Preț: 436.42 lei
-
5%
Preț: 886.59 lei
-
5%
Preț: 1229.45 lei
-
5%
Preț: 1026.70 lei
-
5%
Preț: 1086.74 lei
-
5%
Preț: 1025.85 lei
-
5%
Preț: 1392.17 lei
-
5%
Preț: 1396.27 lei
-
5%
Preț: 970.65 lei
-
5%
Preț: 1089.85 lei
-
5%
Preț: 268.09 lei
-
5%
Preț: 1089.85 lei
-
5%
Preț: 1422.09 lei
-
5%
Preț: 992.48 lei
-
5%
Preț: 1096.06 lei
Preț: 380.72 lei
Preț vechi: 400.75 lei
-5%
Puncte Express: 571
Preț estimativ în valută:
73.28€ • 77.52$ • 61.67£
73.28€ • 77.52$ • 61.67£
Carte tipărită la comandă
Livrare economică 24 august-07 septembrie
Livrare express 19-27 iulie pentru 193.70 lei
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9783211816196
ISBN-10: 3211816194
Pagini: 172
Ilustrații: VIII, 160 p.
Dimensiuni: 152 x 229 x 9 mm
Greutate: 0.33 kg
Ediția: Softcover reprint of the original 1st ed. 1981
Editura: SPRINGER VIENNA
Colecția Springer
Seria Acta Neurochirurgica Supplement
Locul publicării: Vienna, Austria
ISBN-10: 3211816194
Pagini: 172
Ilustrații: VIII, 160 p.
Dimensiuni: 152 x 229 x 9 mm
Greutate: 0.33 kg
Ediția: Softcover reprint of the original 1st ed. 1981
Editura: SPRINGER VIENNA
Colecția Springer
Seria Acta Neurochirurgica Supplement
Locul publicării: Vienna, Austria
Public țintă
ResearchCuprins
1. Introduction.- 2. The Regulation of Glucose Metabolism.- 2.1. Non-Nervous Regulation.- 2.1.1. Intrinsic Cell Mechanisms.- 2.1.2. Hormonal Action.- 2.1.2.1. Insulin.- 2.1.2.2. Glucagon.- 2.1.2.3. Glucocorticoids.- 2.1.2.4. Growth Hormone.- 2.2. Central Nervous Regulation.- 2.2.1. Neural Regulation.- 2.2.1.1. Early Experimental Findings in Animals.- 2.2.1.2. “Neurotraumatic” Diabetes.- 2.2.1.3. Diencephalic Structures and Organization of the Autonomie Nervous System. Results of Stimulation and Ablation Experiments.- 2.2.1.4. Neural Influences on the Liver Cells, on Glycogenolysis and Glycogen Synthesis.- 2.2.1.5. Neural Stimulation of the Adrenal Medulla and the Role of Catecholamines.- 2.2.1.6. Nerve Supply to the Cells of the Islets of Langerhans.- 2.2.1.7. Neural Control of Glucagon Secretion.- 2.2.1.8. Neural Control of Insulin Secretion.- 2.2.2. Neurohumoral Regulation.- 2.2.2.1. The Hypothalamic-Pituitary System.- 2.2.2.2. Glucose-Sensitive Neurones in the Hypothalamus.- 2.2.2.3. Effect of the Location of Diencephalic Lesions on the Clinical and Endocrine Symptoms.- 2.3. Summary.- 3. Methods Employed.- 3.1 Standardization of the Withdrawal of Blood.- 3.2 Standardization of the Loading Tests.- 3.2.1. Intravenous Glucose Load.- 3.2.2. Insulin Hypoglycaemia.- 3.2.3. Arginine “Stress”.- 3.2.4. Somatostatin Load.- 3.3 Chemical Estimation Methods.- 3.3.1. Glucose.- 3.3.2. Free Fatty Acids.- 3.3.3. Human Growth Hormone.- 3.3.4. Insulin.- 3.3.5. Cortisol.- 3.3.6. Glucagon.- 3.3.7. Catecholamines.- 3.4 Pharmacokinetics of Glucose.- 3.5 Statistical Methods.- 4. Results.- 4.1. Survey of Material and Subdivision into Groups.- 4.2. Preliminary Studies.- 4.3. Spontaneous Behaviour.- 4.3.1. Severe Closed Craniocerebral Injury, Acute Subdural Haematoma, Secondary Coma and Midbrain Syndrome.- 4.3.2. Acute Midbrain Syndrome with Extensive Intracranial Haemorrhage.- 4.3.3. Severe Craniocerebral Injury, Acute Hypothalamic Damage.- 4.3.4. Acute Hypothalamic Damage with Transition into a Midbrain Syndrome, Bulbar Damage and Brain Death After Embolization of an A.V. Angioma.- 4.3.5. Hypothalamic Damage After Operation on a Medial Sphenoidal Wing Meningioma.- 4.4. Intravenous “Stress” with Glucose 0.33 g/kg Body Weight.- 4.4.1. Healthy Subjects.- 4.4.2. Diabetics.- 4.4.3. All Intracranial Tumours.- 4.4.3 a. Pre-Operative.- 4.4.3 b. First Post-Operative Day.- 4.4.3 c. Seventh Post-Operative Day.- 4.4.4. Endocrine Inactive Intra- and Suprasellar Pituitary Tumours.- 4.4.4 a. Pre-Operative.- 4.4.4 b. First Post-Operative Day.- 4.4.4 c. Seventh Post-Operative Day.- 4.4.5. Endocrine Active Eosinophilie Adenomas with Pathological HGH Secretion.- 4.4.5 a. Pre-Operative.- 4.4.5 b. First Post-Operative Day.- 4.4.5 c. Seventh Post-Operative Day.- 4.4.6. Patients with Complete Anterior Pituitary Failure.- 4.4.7. Para-Hypothalamic Tumours with Mechanical Changes, Displacement and Chronic Damage.- 4.4.7 a. Pre-Operative.- 4.4.7 b. First Post-Operative Day.- 4.4.8. Patients with Hemisphere Tumours Close to the Cortex.- 4.4.8 a. Pre-Operative.- 4.4.8 b. First Post-Operative Day.- 4.4.8 c. Seventh Post-Operative Day.- 4.4.9. Unconscious Patients with Acute “Midbrain Syndrome”.- 4.4.10. Unconscious Patients with Acute Mesencephalo-Ponto-Bulbar Lesions.- 4.4.11. Unconscious Patients, Regardless of the Site and Level of the Lesion, or the Cerebral Cause.- 4.4.12. Unconscious Patients with the Clinical Signs of Brain Death.- 4.4.13. Patients with Complete Lesions of the Upper Cervical Cord.- 4.5. Mean Hourly Concentrations in the Various Groups, in Response to a Glucose Load.- 4.5.1. Glucose.- 4.5.2. Insulin.- 4.5.3. Human Growth Hormone.- 4.5.4. Cortisol.- 4.5.5. Glucagon.- 4.5.6. Mean Concentrations of the Catecholamines in 24 Hour Urine.- 4.6. The Molar Insulin-Glucagon Quotient in the Various Groups.- 4.7. Pharmacokinetic Investigation of the Concentration Pattern and of the Assimilation of the Blood Glucose After an Intravenous Glucose Load.- 4.7.1. Glucose Assimilation.- 4.7.2. Glucose Transfer.- 4.8. Inhibition Tests with Somatostatin.- 5. Consideration of the Results and Discussion.- 6. Summary.- References.